Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WTX-124 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| WTX-124 monotherapy dose escalation | EXPERIMENTAL | WTX-124 monotherapy dose escalation |
| WTX-124 in combination with pembro dose escalation | EXPERIMENTAL | WTX-124 in combination with pembrolizumab (pembro) dose escalation |
| Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC. | EXPERIMENTAL | Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC. |
| Arm B: WTX-124 monotherapy dose expansion. Advanced or metastatic cutaneous malignant melanoma. | EXPERIMENTAL | Arm B: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cutaneous malignant melanoma. |
| Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC. | EXPERIMENTAL | Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC. |
| Arm D: WTX-124 in combination with pembro dose expansion. Advanced or metastatic RCC. | EXPERIMENTAL | Arm D: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic RCC. |
| Arm E: WTX-124 with pembro dose expansion. Advanced or metastatic cutaneous melanoma. | EXPERIMENTAL | Arm E: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic cutaneous melanoma. |
| Arm F: WTX-124 in combination with pembro dose expansion. Advanced/metastatic PD-L1-positive NSCL | EXPERIMENTAL | Arm F: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic PD-L1-positive NSCLC lines. |
| Name | Type | Description |
|---|---|---|
| WTX-124 | DRUG | Investigation Product Monotherapy |
| pembrolizumab | DRUG | Investigation Product in combination with approved therapy |
Inclusion Criteria: Each patient must meet all the following criteria to participate in the study: 1. Has histological or cytological documentation of a solid tumor indication for which a CPI (e.g. anti-PD-(L)1 is indicated for all parts of the clinical study; 2. Monotherapy Dose Escalation: P...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
WTX-124 is an investigational small molecule being developed for the treatment of metastatic solid tumors. It is currently in Phase 1 clinical development, and the completed trial studied it as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors.
WTX-124 is being developed by Werewolf Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol HOWL. The company is conducting clinical research on this investigational oncology drug.
WTX-124 is in Phase 1 clinical development. The completed trial was a dose escalation and expansion study. It is an investigational drug and has not been approved by regulatory authorities. The FDA has granted it Fast Track designation.
WTX-124 has one completed clinical trial, identified as NCT05479812. This Phase 1 study evaluated WTX-124 as monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors. The trial enrolled 156 participants in the United States.
No, WTX-124 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The FDA has granted it Fast Track designation, which is intended to expedite development and review, but approval has not been granted.